{
  "id": 13488905,
  "title": "Israeli Pharma Giant Teva wins FDA approval for monthly schizophrenia injection Weltruza",
  "url": "https://urgent.news/2026/10/10/israeli-pharma-giant-teva-wins-fda-approval-for-monthly-schizophrenia",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-10T17:50:22.000Z",
  "source": {
    "name": "Haaretz",
    "slug": "haaretz",
    "url": "https://www.haaretz.com/science-and-health/2026-10-10/ty-article/israeli-pharma-giant-teva-wins-fda-approval-for-monthly-schizophrenia-injection/000001a1-26da-de05-a9a9-3ffe2fde0000"
  },
  "original_language": "en",
  "account": "Teva Pharmaceutical Industries Ltd., an Israeli pharma giant, announced on Friday that the U.S. Food and Drug Administration (FDA) had approved Weltruza, a once-monthly injection for adults with schizophrenia. Weltruza is the second product to receive U.S. approval under Teva's collaboration with French biotech company Medincell, following Uzedy, a long-acting injectable form of antipsychotic drug risperidone, which the FDA approved in 2023. Teva is overseeing the development and commercialization of Weltruza.\n\nThe new drug employs Medincell's long-acting injectable technology to release medication over an extended period. This innovation aims to tackle treatment-adherence issues prevalent among patients with chronic psychiatric conditions. Long-acting olanzapine formulations have shown promise in managing schizophrenia, according to analysts. In the agreement, Medincell stands to earn up to $112 million in development and commercial milestone payments, along with royalties on sales.\n\nTeva's shares surged 2 percent higher in Tel Aviv, while Medincell's shares climbed 16.9 percent in Paris following the FDA's approval.",
  "summary": "Weltruza is Teva's second U.S.-approved product made in partnership with French biotech company Medincell. It uses long-acting injectable technology, designed to release medication over an extended period",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}